GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Gross-Profit-to-Asset %

4basebio (XTER:88Q) Gross-Profit-to-Asset % : 2.79% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 4basebio Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. 4basebio's annualized Gross Profit for the quarter that ended in Jun. 2023 was €0.38 Mil. 4basebio's average Total Assets over the quarter that ended in Jun. 2023 was €13.45 Mil. Therefore, 4basebio's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 2.79%.


4basebio Gross-Profit-to-Asset % Historical Data

The historical data trend for 4basebio's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Gross-Profit-to-Asset % Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Gross-Profit-to-Asset %
-2.42 2.88 1.71 1.79

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross-Profit-to-Asset % Get a 7-Day Free Trial 1.75 1.72 1.69 2.05 2.79

Competitive Comparison of 4basebio's Gross-Profit-to-Asset %

For the Biotechnology subindustry, 4basebio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4basebio's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4basebio's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where 4basebio's Gross-Profit-to-Asset % falls into.



4basebio Gross-Profit-to-Asset % Calculation

4basebio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0.275/( (17.302+13.44)/ 2 )
=0.275/15.371
=1.79 %

4basebio's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=0.376/( (13.44+13.467)/ 2 )
=0.376/13.4535
=2.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


4basebio Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of 4basebio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


4basebio (XTER:88Q) Business Description

Traded in Other Exchanges
Address
25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines